Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | bmru protein, putative | 0.0083 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0083 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0083 | 0 | 0.5 |
Trichomonas vaginalis | bmru protein, putative | 0.0083 | 0 | 0.5 |
Trypanosoma brucei | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Trypanosoma cruzi | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Leishmania major | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Trypanosoma brucei | Sphingosine kinase | 0.0083 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Trypanosoma cruzi | Sphingosine kinase | 0.0083 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0083 | 0 | 0.5 |
Trypanosoma brucei | Diacylglycerol kinase catalytic domain containing protein, putative | 0.0083 | 0 | 0.5 |
Trypanosoma cruzi | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Plasmodium vivax | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0083 | 0 | 0.5 |
Trypanosoma cruzi | Diacylglycerol kinase catalytic domain containing protein, putative | 0.0083 | 0 | 0.5 |
Toxoplasma gondii | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0183 | 0.0492 | 0.0492 |
Schistosoma mansoni | sphingoid long chain base kinase | 0.2125 | 1 | 1 |
Plasmodium falciparum | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.2125 | 1 | 1 |
Trypanosoma cruzi | diacylglycerol kinase-like protein, putative | 0.0083 | 0 | 0.5 |
Plasmodium vivax | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, zeta, iota, putative | 0.0083 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, zeta, iota, putative | 0.0083 | 0 | 0.5 |
Schistosoma mansoni | sphingosine kinase A B | 0.2125 | 1 | 1 |
Onchocerca volvulus | Ceramide kinase 1 homolog | 0.0083 | 0 | 0.5 |
Toxoplasma gondii | diacylglycerol kinase accessory domain (presumed) domain-containing protein | 0.0083 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein, conserved | 0.2125 | 1 | 1 |
Trichomonas vaginalis | diacylglycerol kinase, epsilon, putative | 0.0083 | 0 | 0.5 |
Brugia malayi | Cytochrome P450 family protein | 0.0183 | 0.0492 | 1 |
Echinococcus multilocularis | sphingosine kinase 1 | 0.2125 | 1 | 1 |
Trichomonas vaginalis | sphingosine kinase, putative | 0.0083 | 0 | 0.5 |
Trypanosoma cruzi | Sphingosine kinase | 0.0083 | 0 | 0.5 |
Leishmania major | sphingosine kinase A, B, putative | 0.0083 | 0 | 0.5 |
Plasmodium falciparum | diacylglycerol kinase, putative | 0.0083 | 0 | 0.5 |
Trichomonas vaginalis | sphingosine kinase, putative | 0.0083 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.2125 | 1 | 1 |
Leishmania major | diacylglycerol kinase-like protein | 0.0083 | 0 | 0.5 |
Trypanosoma cruzi | diacylglycerol kinase-like protein, putative | 0.0083 | 0 | 0.5 |
Onchocerca volvulus | 0.0083 | 0 | 0.5 | |
Leishmania major | hypothetical protein, conserved | 0.0083 | 0 | 0.5 |
Toxoplasma gondii | diacylglycerol kinase catalytic domain-containing protein | 0.0083 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2125 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 17 uM | In vitro cytotoxicity against murine B16 melanoma cells | ChEMBL. | 3681888 |
MTD (functional) | = 5 uM kg-1 | Maximally tolerated dose was measured after ip administration of compound, 24 hr after tumor implantation. | ChEMBL. | 3681888 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.